143,532 Shares in Profound Medical $PROF Acquired by Empery Asset Management LP

Posted by George Bondi on Jun 11th, 2026

Empery Asset Management LP purchased a new position in shares of Profound Medical (NASDAQ:PROF – Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 143,532 shares of the company’s stock, valued at approximately $1,130,000. Profound Medical makes up approximately 1.0% of Empery Asset Management LP’s portfolio, making the stock its 13th largest position.

Several other hedge funds and other institutional investors have also recently bought and sold shares of PROF. First Eagle Investment Management LLC lifted its position in Profound Medical by 138.8% during the 3rd quarter. First Eagle Investment Management LLC now owns 291,391 shares of the company’s stock worth $1,451,000 after acquiring an additional 169,352 shares in the last quarter. Royce & Associates LP increased its holdings in Profound Medical by 15.2% during the 4th quarter. Royce & Associates LP now owns 990,348 shares of the company’s stock worth $7,771,000 after purchasing an additional 130,442 shares during the last quarter. Zweig DiMenna Associates LLC purchased a new stake in Profound Medical during the 4th quarter worth approximately $1,023,000. Perkins Capital Management Inc. purchased a new stake in Profound Medical during the 4th quarter worth approximately $899,000. Finally, Legato Capital Management LLC purchased a new stake in Profound Medical during the 4th quarter worth approximately $784,000. 47.86% of the stock is owned by institutional investors and hedge funds.

Profound Medical Trading Down 1.6%

Shares of NASDAQ PROF opened at $6.71 on Thursday. Profound Medical has a twelve month low of $3.76 and a twelve month high of $8.95. The company has a market capitalization of $243.84 million, a price-to-earnings ratio of -5.41 and a beta of 0.72. The business has a 50 day simple moving average of $6.74 and a 200-day simple moving average of $6.90.

Profound Medical (NASDAQ:PROF – Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.05. Profound Medical had a negative return on equity of 78.88% and a negative net margin of 206.76%.The business had revenue of $5.34 million during the quarter, compared to the consensus estimate of $4.85 million. As a group, equities analysts predict that Profound Medical will post -0.88 earnings per share for the current year.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded Profound Medical from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 22nd. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Profound Medical presently has an average rating of “Hold” and an average price target of $12.00.

View Our Latest Stock Report on PROF

Profound Medical Company Profile

(Free Report)

Profound Medical Corp is a medical technology company headquartered in Toronto, Canada, that specializes in the development and commercialization of minimally invasive therapeutic solutions using magnetic resonance–guided ultrasound ablation. The company’s proprietary platform delivers focused ultrasound energy to targeted tissue under real-time MR imaging, offering a non-incisional alternative to traditional surgical approaches.

The company’s lead product, the TULSA-PRO system, is designed for the treatment of prostate conditions, including localized prostate cancer and benign prostatic hyperplasia.